Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736696 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
A Phase 1 study of Psoriasis and Immunomodulation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT01736696: Completed Phase 1 study of Psoriasis and Immunomodulation, sponsored by Pfizer.
NCT01736696 is a Phase 1 study of Psoriasis and Immunomodulation that has completed, run by Pfizer. The registered enrollment target is 59 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01736696, a Phase 1 study of Psoriasis and Immunomodulation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.
Primary Outcome
Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated.QT interval: The time corresponding to the beginning of depolarization to repolarization of the ventricles. For each scheduled hour post morning dose (HPD), except for HPD=0, the time-matched baseline QT was defined as the mean of the triplicates on Day 0 at the same nominal HPD.
Conditions Studied
Interventions
- DRUG tofacitinib
Study Locations (1)
Arkansas
- Pfizer Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
What the finished NCT01736696 record still lists
NCT01736696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which tofacitinib is the first listed.
NCT01736696 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT01736696 about?
NCT01736696 is a clinical study titled "Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis". This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing saf...
What is the current status of trial NCT01736696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2002-11. Estimated completion is 2004-04.
What conditions does trial NCT01736696 study?
This clinical trial studies the following conditions: Psoriasis, Immunomodulation.
What interventions are being tested in trial NCT01736696?
The interventions under investigation include: tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01736696?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01736696 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01736696's enrollment target sits among peer trials
59 73rd of 125 higher than 52 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia